#1484 Systematic Review and Meta-analysis of the Association Between CONUT Score and High-Grade Postoperative Complications in Bladder Cancer Patients Undergoing Radical Cystectomy
#232
NEW INSIGHTS ABOUT THE ROLE OF FSH THERAPY IN IDIOPATHIC MALE INFERTILITY
Nguyen Huynh Dang Khoa1, Nguyen Ngoc Thai2, Nguyen Huu Hoang Quan1
1 University
of Medicine and Pharmacy at Ho Chi Minh city, Urology, Ho Chi Minh City,
2 University of Medicine and Pharmacy at Ho Chi Minh city,
Urology, HO CHI MINH CITY
Introduction:
Despite advancements in assisted reproductive technology (ART), the treatment
of idiopathic male infertility (IMI) remains suboptimal. Current management is
largely empirical, relying on small observational studies rather than robust
clinical trials and strong evidence. Among the available options,
Follicle-stimulating hormone (FSH) has shown potential in improving sperm
parameters and achieving clinical pregnancies in IMI cases. This review aims to
update recent findings on the efficacy of FSH therapy in IMI and explore the
potential application of the novel APHRODITE criteria for male infertility
patients undergoing hormonal treatment.
Materials and Methods:
A comprehensive literature review was conducted up to December 2024, focusing
on studies evaluating the effects of FSH on semen parameters, sperm DNA
fragmentation (SDF), and pregnancy outcomes (natural or ART-mediated) in IMI
patients. Recent clinical guidelines for hormonal treatment of IMI were also
reviewed. Additionally, the APHRODITE criteria were analyzed for their
potential to classify infertile males systematically and propose a structured
approach to hormonal treatment.
Results:
Studies have demonstrated significant improvements in semen parameters,
including sperm concentration, total count, motility, and reduced SDF following
FSH therapy. Pregnancy rates after treatment were also promising. The common
dosage of 150 IU administered every other day for three months showed efficacy,
while higher doses and prolonged treatment duration yielded even greater
benefits. The APHRODITE criteria present a systematic framework for managing
IMI patients (group 2), offering a structured approach to candidate selection
and treatment planning.